Education
About Us
Working with TipRanks
Follow Us
Myriad Genetics (MYGN)
NASDAQ:MYGN
Total Valuation
Myriad Genetics has a market cap or net worth of $435.75M. The enterprise value is $495.95M.
Market Cap$435.75M
Enterprise Value$495.95M
Share Statistics
Myriad Genetics has 93,508,160 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding93,508,160
Owned by Insiders4.56%
Owned by Institutions7.10%
Financial Efficiency
Myriad Genetics’s return on equity (ROE) is -0.99 and return on invested capital (ROIC) is -22.25%.
Return on Equity (ROE)-0.99
Return on Assets (ROA)-0.52
Return on Invested Capital (ROIC)-22.25%
Return on Capital Employed (ROCE)-0.24
Revenue Per Employee305.37K
Profits Per Employee0.00
Employee Count2,700
Asset Turnover1.17
Inventory Turnover8.10
Valuation Ratios
The current PE Ratio of Myriad Genetics is ―. Myriad Genetics’s PEG ratio is -0.00867.
PE Ratio―
PS Ratio0.70
PB Ratio1.56
Price to Fair Value1.56
Price to FCF318.77
Price to Operating Cash Flow241.54
PEG Ratio-0.00867
Income Statement
In the last 12 months, Myriad Genetics had revenue of 824.50M and earned -365.90M in profits. Earnings per share was -3.96.
Revenue824.50M
Gross Profit576.60M
Operating Income-139.30M
Pretax Income-395.10M
Net Income-365.90M
EBITDA-397.40M
Earnings Per Share (EPS)-3.96
Cash Flow
In the last 12 months, operating cash flow was 1.80M and capital expenditures -18.00M, giving a free cash flow of -16.20M billion.
Operating Cash Flow1.80M
Free Cash Flow-16.20M
Free Cash Flow per Share-0.17
Dividends & Yields
Myriad Genetics pays an annual dividend of $1.75, resulting in a dividend yield of ―
Dividend Per Share$1.75
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.63
52-Week Price Change-53.95%
50-Day Moving Average5.38
200-Day Moving Average6.10
Relative Strength Index (RSI)41.38
Average Volume (3m)1.63M
Important Dates
Myriad Genetics upcoming earnings date is Apr 30, 2026, TBA (Confirmed).
Last Earnings DateFeb 23, 2026
Next Earnings DateApr 30, 2026
Ex-Dividend Date―
Financial Position
Myriad Genetics as a current ratio of 2.49, with Debt / Equity ratio of 57.01%
Current Ratio2.49
Quick Ratio2.26
Debt to Market Cap0.37
Net Debt to EBITDA-0.15
Interest Coverage Ratio-11.51
Taxes
In the past 12 months, Myriad Genetics has paid -29.20M in taxes.
Income Tax-29.20M
Effective Tax Rate0.07
Enterprise Valuation
Myriad Genetics EV to EBITDA ratio is -1.60, with an EV/FCF ratio of 352.22.
EV to Sales0.77
EV to EBITDA-1.60
EV to Free Cash Flow352.22
EV to Operating Cash Flow352.22
Balance Sheet
Myriad Genetics has $149.60M in cash and marketable securities with $209.80M in debt, giving a net cash position of -$60.20M billion.
Cash & Marketable Securities$149.60M
Total Debt$209.80M
Net Cash-$60.20M
Net Cash Per Share-$0.64
Tangible Book Value Per Share$1.75
Margins
Gross margin is 69.93%, with operating margin of -16.90%, and net profit margin of -44.38%.
Gross Margin69.93%
Operating Margin-16.90%
Pretax Margin-47.92%
Net Profit Margin-44.38%
EBITDA Margin-48.20%
EBIT Margin-46.45%
Analyst Forecast
The average price target for Myriad Genetics is $6.58, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$6.58
Price Target Upside41.20% Upside
Analyst ConsensusHold
Analyst Count8
Revenue Growth Forecast0.21%
EPS Growth Forecast-233.51%